MedTrace Logo

Mirabegron in Patients With Age-Related Macular Degeneration

NCT07305298 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 312

Last updated 2026-02-06

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.

The main question it aims to answer is:

• Is there any change in outer retina morphology in patients treated?

Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.

Participants will:

* Take Mirabegron or Solifenacin every day for 12 months
* Visit the clinic once every 6 months for checkups and tests

Conditions

Interventions

DRUG

Mirabegron 50mg

Mirabegron (50mg/day per os) will be administered in patients with dry AMD and overactive bladder (MMirabegron arm)

DRUG

Solifenacin 5mg

Solifenacin (5mg/day per os) will be administered in control group (dry amd and overactive bladder)

Sponsors & Collaborators

  • Medical University of Lublin

    collaborator OTHER

  • University of Naples

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2026-12-01
Completion
2026-12-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07305298 on ClinicalTrials.gov